Tuesday, February 28, 2012 - 6:30pm

Human immunodeficiency virus (HIV) targets white blood cells, specifically CD4 lymphocytes, resulting in acquired immunodeficiency syndrome (AIDS). When CD4 cell levels decrease, life-threatening opportunistic infections and cancers thrive more often than not resulting in death.  As a result, CD4 levels are often used to monitor disease progression. However, HIV prevalence is highest in resource-limited areas where regular monitoring is not readily available for HIV infected individuals resulting in patient loss prior to antiretroviral treatment.

ChipCare hopes to address this problem with their portable CD4 count lab-on-a-chip. Portability, rapid results and low costs compared to traditional flow cytometry are examples of the many advantages of this novel technology.  Although a benchtop prototype has been developed thus far, the production of handheld analyzer will be able to make blood testing more accessible, efficient and affordable for a variety of pathogens including HIV. ChipCare’s technology uses passive capillary flow cytometry to provide absolute CD4 counts for patients in resource-limited areas.  

Team BioLOGIC will provide guidance to ChipCare by providing insight on the clinical trial design and regulatory approval in resource-limited countries.  Join team bioLOGIC on Tuesday February 28th, 2012 at 6:30pm as they provide the regulatory pathway to market this lab-on-a-chip in Thailand and make monitoring HIV more convenient.

Team BioLOGIC: Hina Abbas, Jean Frederic Comeau, Peter Le, Sandeep Sehgal

Tuesday, February 21, 2012, 6:30-7:30pm, Instructional Centre, Room 335. Also available via webcast. Open to the public.

The Master of Biotechnology Program would like to thank AstraZeneca Canada Inc. for their continued support of this seminar series.